drugset / Trial / NCT01192243
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2009-12
- Primary completion
- 2011-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |